Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
<p>PFS before and after palbociclib dose change</p>
Publications
7 shownSupplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
<p>Serious adverse events</p>
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
<p>Representativeness of the study participants</p>
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in b...
Supplementary Table S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
<p>Characteristics of CNS cohort</p>
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
<p>Grade 3 and 4 AEs - palbociclib 125mg vs 75mg</p>
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 7
- Citations
- 1,224
- Institution
- University of Colorado Cancer Center
External Links
Identifiers
- ORCID
- 0000-0003-1158-7524
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.